LC
AVBP icon

Lindbrook Capital’s ArriVent BioPharma AVBP Stock Holding History

Lindbrook Capital’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.18K Buy
+118
New +$2.89K ﹤0.01% 2258

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lindbrook Capital's AVBP Position: Q1 2025 in Review

Lindbrook Capital opened a new position in ArriVent BioPharma (AVBP) in Q1 2025: 118 shares worth $2.18K. The stake represents ﹤0.01% of the portfolio and ranks #2258 among its holdings.

83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

  • Lindbrook Capital held 118 shares of ArriVent BioPharma worth $2.18K as of Q1 2025.
  • ArriVent BioPharma was a new Lindbrook Capital position in Q1 2025.
  • ArriVent BioPharma made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2258 holding.
  • 83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.